Accéder au contenu
Merck

Nr5a2 maintains acinar cell differentiation and constrains oncogenic Kras-mediated pancreatic neoplastic initiation.

Gut (2013-05-07)
Guido von Figura, John P Morris, Christopher V E Wright, Matthias Hebrok
RÉSUMÉ

Emerging evidence from mouse models suggests that mutant Kras can drive the development of pancreatic ductal adenocarcinoma (PDA) precursors from acinar cells by enforcing ductal de-differentiation at the expense of acinar identity. Recently, human genome-wide association studies have identified NR5A2, a key regulator of acinar function, as a susceptibility locus for human PDA. We investigated the role of Nr5a2 in exocrine maintenance, regeneration and Kras driven neoplasia. To investigate the function of Nr5a2 in the pancreas, we generated mice with conditional pancreatic Nr5a2 deletion (PdxCre(late); Nr5a2(c/c)). Using this model, we evaluated acinar differentiation, regeneration after caerulein pancreatitis and Kras driven pancreatic neoplasia in the setting of Nr5a2 deletion. We show that Nr5a2 is not required for the development of the pancreatic acinar lineage but is important for maintenance of acinar identity. Nr5a2 deletion leads to destabilisation of the mature acinar differentiation state, acinar to ductal metaplasia and loss of regenerative capacity following acute caerulein pancreatitis. Loss of Nr5a2 also dramatically accelerates the development of oncogenic Kras driven acinar to ductal metaplasia and PDA precursor lesions. Nr5a2 is a key regulator of acinar plasticity. It is required for maintenance of acinar identity and re-establishing acinar fate during regeneration. Nr5a2 also constrains pancreatic neoplasia driven by oncogenic Kras, providing functional evidence supporting a potential role as a susceptibility gene for human PDA.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Tamoxifène, ≥99%
Sigma-Aldrich
Dexaméthasone, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
DAPI, for nucleic acid staining
Sigma-Aldrich
Dexaméthasone, ≥98% (HPLC), powder
Sigma-Aldrich
Caerulein, ≥95% (HPLC)
Sigma-Aldrich
Dexaméthasone, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
USP
Dexaméthasone, United States Pharmacopeia (USP) Reference Standard
Supelco
Dexaméthasone, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Tamoxifen citrate salt, ≥99%
Supelco
Tamoxifène, analytical standard
Sigma-Aldrich
Dexaméthasone, meets USP testing specifications
Sigma-Aldrich
Dexaméthasone, tested according to Ph. Eur.
Supelco
Dexaméthasone, VETRANAL®, analytical standard
Dexaméthasone, European Pharmacopoeia (EP) Reference Standard
Dexaméthasone, European Pharmacopoeia (EP) Reference Standard
Dexaméthasone, British Pharmacopoeia (BP) Assay Standard
Tamoxifen citrate, European Pharmacopoeia (EP) Reference Standard
Tamoxifen citrate for performance test, European Pharmacopoeia (EP) Reference Standard
Dexaméthasone, European Pharmacopoeia (EP) Reference Standard